FDA approves Talzenna for germline BRCA-mutated HER2-negative breast cancer Oct. 17, 2018 No Comments
FDA approves Vizimpro for first-line treatment of metastatic NSCLC with EGFR mutations Sep. 28, 2018 No Comments
RSS